251 related articles for article (PubMed ID: 35486401)
1. Effectiveness of Immune Checkpoint Inhibition vs Chemotherapy in Combination With Radiation Therapy Among Patients With Non-Small Cell Lung Cancer and Brain Metastasis Undergoing Neurosurgical Resection.
Wasilewski D; Radke J; Xu R; Raspe M; Trelinska-Finger A; Rosenstock T; Poeser P; Schumann E; Lindner J; Heppner F; Kaul D; Suttorp N; Vajkoczy P; Frost N; Onken J
JAMA Netw Open; 2022 Apr; 5(4):e229553. PubMed ID: 35486401
[TBL] [Abstract][Full Text] [Related]
2. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
Takamori S; Komiya T; Powell E
Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
[TBL] [Abstract][Full Text] [Related]
3. Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Zhu KK; Wei JL; Xu YH; Li J; Rao XR; Xu YZ; Xing BY; Zhang SJ; Chen LC; Dong XR; Zhang S; Li ZY; Liu CW; Meng R; Wu G
Curr Med Sci; 2023 Apr; 43(2):344-359. PubMed ID: 37002471
[TBL] [Abstract][Full Text] [Related]
4. Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non-Small-Cell Lung Cancer and Synchronous Brain Metastases.
Mahashabde R; Bhatti SA; Martin BC; Painter JT; Rodriguez A; Ying J; Li C
JCO Oncol Pract; 2023 Nov; 19(11):1009-1019. PubMed ID: 37729600
[TBL] [Abstract][Full Text] [Related]
5. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
[TBL] [Abstract][Full Text] [Related]
6. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bongiovanni A; Foca F; Menis J; Stucci SL; Artioli F; Guadalupi V; Forcignanò MR; Fantini M; Recine F; Mercatali L; Spadazzi C; Burgio MA; Fausti V; Miserocchi A; Ibrahim T
Front Immunol; 2021; 12():697298. PubMed ID: 34858389
[TBL] [Abstract][Full Text] [Related]
8. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
Kuo CS; Wang CC; Huang YC; Pavlidis S; Liu CY; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
Thorac Cancer; 2019 May; 10(5):1158-1166. PubMed ID: 30950239
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes.
Nassar AH; El Zarif T; Khalid AB; Rahme S; Zhong C; Kwak L; Salame M; Farhat EB; Freeman D; El-Am E; Ravishankar A; Ahmad B; Nana FA; Kaldas D; Naqash AR; Sharon E; LeBoeuf NR; Cortellini A; Malgeri A; Gupta S; Al-Hader A; Sparks JA; Linnoila J; Hamnvik OR; Mouhieddine TH; Marron T; Parikh K; McKay RR; Dilling T; Choueiri TK; Adib E; Najem E; Kim SY; Sonpavde G
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38448038
[TBL] [Abstract][Full Text] [Related]
10. Intracranial activity of first-line immune checkpoint inhibitors combined with chemotherapy in advanced non-small cell lung cancer.
Huang Z; Wu F; Xu Q; Song L; Zhang X; Wang Z; Deng L; Zhang Y; Zeng L; Yang N
Chin Med J (Engl); 2023 Jun; 136(12):1422-1429. PubMed ID: 37195128
[TBL] [Abstract][Full Text] [Related]
11. Central nervous systemic efficacy of immune checkpoint inhibitors and concordance between intra/extracranial response in non-small cell lung cancer patients with brain metastasis.
Kang S; Jeong H; Park JE; Kim HS; Kim YH; Lee DH; Kim SW; Lee JC; Choi CM; Yoon S
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4523-4532. PubMed ID: 36136277
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non-Small Cell Lung Cancer.
Uhlig J; Case MD; Blasberg JD; Boffa DJ; Chiang A; Gettinger SN; Kim HS
JAMA Netw Open; 2019 Aug; 2(8):e199702. PubMed ID: 31433481
[TBL] [Abstract][Full Text] [Related]
13. Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy.
Lau SCM; Poletes C; Le LW; Mackay KM; Fares AF; Bradbury PA; Shepherd FA; Tsao MS; Leighl NB; Liu G; Shultz D; Sacher AG
Lung Cancer; 2021 Jun; 156():76-81. PubMed ID: 33932863
[TBL] [Abstract][Full Text] [Related]
14. Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors.
Said JT; Liu M; Talia J; Singer SB; Semenov YR; Wei EX; Mostaghimi A; Nelson CA; Giobbie-Hurder A; LeBoeuf NR
JAMA Dermatol; 2022 May; 158(5):552-557. PubMed ID: 35416925
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
[TBL] [Abstract][Full Text] [Related]
16. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
[TBL] [Abstract][Full Text] [Related]
17. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis.
Qiu L; Gao S; Du S; Sun S; Liang Y; Sun Z; Li T; Jia G; Li K; Sun X; Jiao S; Zhao X
Front Oncol; 2022; 12():974227. PubMed ID: 36523994
[TBL] [Abstract][Full Text] [Related]
19. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
[TBL] [Abstract][Full Text] [Related]
20. Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases.
Yang G; Xing L; Sun X
Front Immunol; 2022; 13():852811. PubMed ID: 35422812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
